Downloads
White Paper: Ten Most Common Reasons For FDA 483 Observations And Warning Letter Citations
Source:
MasterControl
At a recent Intermountain Biomedical Association workshop held in Lehi, Utah, Barbara Cassens, Director of the FDA's San Francisco District Office, identified ten specific FDA regulated areas in which medical device companies most commonly receive FDA-483 Observations and Warning Letter citations. This white paper also introduces the MasterControl Solution and how it can help avoid FDA 483 Observations and Warning Letters. Submitted by MasterControl
Register Today. It's Fast And Free.
The content you requested is only available to registered users of Pharmaceutical Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
Already Registered? Sign In.
